Seeking Novel CNS Indications and Mechanistic Pathways for RIPK1 Inhibition

A global pharmaceutical company has developed a CNS-penetrant **receptor-interacting protein kinase 1 (RIPK1) inhibitor** and is actively seeking partners with expertise in RIPK1's role in human pathophysiology to **identify promising disease indications** that will guide further development of the inhibitor.

Approaches of Interest:

- Identification of promising CNS disease indications that are driven by the RIPK1 pathway for inhibitor development:
    - Both **genetic rare diseases and common diseases** are acceptable
    - For common diseases, **information that supports patient stratification**—identifying the specific population in which RIPK1 inhibitors demonstrate the most pronounced efficacy—is of high interest
    - Symptoms/pathophysiology that are associated with increased RIPK1 kinase activity or are improved by inhibition of RIPK1 kinase activity in clinical/non-clinical research
- **Pathways modulated by RIPK1 inhibitors** beyond inflammation and necroptosis in the CNS
- Approaches incorporating **RIPK3 and MLKL kinases** that are directly involved in RIPK1 kinase signaling are also of interest

Out of Scope:

- Indications that have already progressed to clinical trials such as ALS, MS, IBD, psoriasis, rheumatoid arthritis, and peripheral artery disease
- Research relating to ischemic stroke, Krabbe disease and Niemann-Pick disease type C
- Opportunities where RIPK1 functions as a protein scaffold

Developmental Stages of Interest:

- Research at basic to late preclinical stages is within scope
- Opportunities with *in vivo* validation are of highest interest

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this submission form. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Please check your organization's external collaboration policy and/or guidelines before submitting to this anonymous campaign, which may result in introduction and subsequent partnering discussions with the client company. Please get in touch with campaigns@inpart.io if you have any queries.

Opportunities sought

- ⏳ Biotech assets
- 🏢 Spinout companies
- ⚗️ Research projects
- 🏆 Centres of excellence
- 🎓 Academics and expertise
- 💡 Technologies

Submissions

Please submit relevant, non-confidential opportunities online here

Deadline: **30th June 2025 - 10:59 pm GMT**

Have any questions?
Contact our team at discover@in-part.co.uk